Washington, D.C. 20549






Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of November, 2023

Commission File Number 001-39670




(Translation of registrant’s name into English)



6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐





On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) announced the commencement of a $50 million share repurchase program (the “Program”) of its ordinary shares of one pence each (“Ordinary Shares”). The Company plans to execute the Program in two equal tranches, the first of which was completed on October 26, 2022. In respect of each of the two tranches, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited (“Jefferies”) in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the second tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company’s general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on June 13, 2023, Chapter 12 of the Financial Conduct Authority’s UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.

During the month ended November 30, 2023, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:




   Ordinary Shares
     Volume Weighted
Average Price Paid
per Ordinary Share
     Highest Price Paid      Lowest Price Paid  

November 1, 2023

     47,566        150.30p        154.80p        149.00p  

November 2, 2023

     35,710        157.86p        161.40p        154.60p  

November 3, 2023

     38,688        158.90p        161.60p        154.00p  

November 6, 2023

     40,474        162.31p        162.80p        161.40p  

November 7, 2023

     24,745        160.94p        163.00p        159.00p  

November 8, 2023

     44,412        163.97p        165.60p        160.40p  

November 9, 2023

     1,835        168.60p        168.60p        168.60p  

November 10, 2023

     42,611        164.81p        171.40p        162.80p  

November 13, 2023

     44,425        170.44p        171.60p        164.00p  

November 14, 2023

     2,116        173.39p        174.00p        173.20p  

November 16, 2023

     25,140        179.00p        182.20p        176.80p  

November 17, 2023

     44,415        176.95p        181.00p        170.60p  

November 20, 2023

     50,034        172.77p        174.60p        171.40p  

November 21, 2023

     52,644        165.60p        172.00p        163.40p  

November 22, 2023

     49,514        166.60p        169.00p        164.40p  

November 23, 2023

     48,600        164.25p        166.20p        161.00p  

November 24, 2023

     32,582        163.39p        165.20p        162.20p  

November 27, 2023

     37,169        162.84p        164.80p        160.40p  

November 28, 2023

     39,084        157.74p        160.20p        156.20p  

November 29, 2023

     35,923        157.58p        160.80p        156.60p  

November 30, 2023

     50,660        154.99p        157.80p        152.20p  

During the month ended November 30, 2023, the Company repurchased an aggregate of 788,347 Ordinary Shares. As of November 30, 2023, the Company’s issued share capital was 289,468,159 shares, 16,751,624 of which were held in treasury, resulting in total voting rights in the Company of 272,716,535 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:

November 1, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4956432.html

November 2, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4957868.html

November 3, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4959395.html

November 6, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4960859.html

November 7, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4962367.html

November 8, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4963913.html

November 9, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4965428.html

November 10, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4966863.html

November 13, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4968374.html

November 14, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4969850.html

November 16, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4972892.html

November 17, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4974299.html

November 20, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4975816.html

November 21, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4977290.html

November 22, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4979125.html

November 23, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4980541.html

November 24, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4981979.html

November 27, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4983534.html

November 28, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4984991.html

November 29, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4986623.html

November 30, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4988247.html


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: December 5, 2023     By:   /s/ Daphne Zohar
      Name: Daphne Zohar
      Title: Chief Executive Officer